Journal of Dermatological Treatment最新文献_第3页

Single-institution retrospective review evaluating the impact of the Covid-19 pandemic on isotretinoin prescribing practices 评估 Covid-19 大流行对异维甲酸处方做法影响的单一机构回顾性研究

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-15 DOI: 10.1080/09546634.2023.2291326

Dina Poplausky, Brandon R. Block, Annie Chang, Sach Thakker, Jade N. Young, Nicholas Gulati, Jonathan Ungar

引用次数: 0

A clinical evaluation of patients with known mutations (plasminogen and factor XII) with a focus on prophylactic treatment 对已知基因突变（纤溶酶原和 XII 因子）患者的临床评估，重点是预防性治疗

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-12 DOI: 10.1080/09546634.2023.2290362

Robin Lochbaum, Susanne Trainotti, Thomas K. Hoffmann, Jens Greve, Janina Hahn

引用次数: 0

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry 银屑病病情严重程度和特殊部位受累对患者报告的真实结果的影响：CorEvitas 银屑病登记处的分析结果

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-11 DOI: 10.1080/09546634.2023.2287401

Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, Adam Sima, Jud Janak, Manish Patel, Huzefa Photowala, Vishvas Garg, Jerry Bagel

引用次数: 0

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis 使用奥达帕替尼早期缓解瘙痒可预测特应性皮炎后期的皮肤清除率

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-11 DOI: 10.1080/09546634.2023.2291317

Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

引用次数: 0

Efficacy and safety of ablative CO₂ fractional laser and narrowband intense pulsed light for the treatment of hypertrophic scars: a prospective, randomized controlled trial. 烧蚀二氧化碳点阵激光和窄带强脉冲光治疗增生性疤痕的有效性和安全性：前瞻性随机对照试验。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 Epub Date: 2023-04-18 DOI: 10.1080/09546634.2023.2202287

Yiqiu Zhang, Rongan Ye, Jiying Dong, Yubing Bai, Yu He, Wei Ni, Min Yao

{"title":"Efficacy and safety of ablative CO2 fractional laser and narrowband intense pulsed light for the treatment of hypertrophic scars: a prospective, randomized controlled trial.","authors":"Yiqiu Zhang, Rongan Ye, Jiying Dong, Yubing Bai, Yu He, Wei Ni, Min Yao","doi":"10.1080/09546634.2023.2202287","DOIUrl":"10.1080/09546634.2023.2202287","url":null,"abstract":"Background and objectives: Hypertrophic scarring is a complex process, and numerous methods have been introduced to treat scars. This study aims to evaluate the effect of combined CO2 fractional laser and narrowband intense pulsed light (IPL) compared to IPL alone in the treatment of hypertrophic scars.Materials and methods: This was a prospective, randomized controlled study enrolled 138 patients with hypertrophic scars. The participants were randomly divided into two groups: CO2-IPL and IPL group, and received three sessions at 10-14-week intervals for 3-month follow-up. Two independent plastic surgeons evaluated the treatments using the Patient and Observer Scar Assessment Scales (POSAS). Overall satisfaction was evaluated using the Patient Satisfaction Scale (PSS).Results: 101 subjects completed the study. Compared to single IPL, the combination CO2-IPL group showed a significant improvement in itching, color, stiffness, thickness, and irregularity, except for pain, and an enhancement in vascularization, pigmentation, thickness, relief, and pliability of the scar, assessed by POSAS (p < .01). 100% patients in the combination group were satisfied compared to 84% in IPL alone.Conclusion: The combination of CO2 fractional laser and narrowband IPL efficiently improved the appearance and profile of hypertrophic scars, offering a comprehensive and reliable approach for scar therapy.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2202287"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study. 透明质酸微填充剂改善浅表皱纹和皮肤质量：一项随机前瞻性对照多中心研究。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 Epub Date: 2023-08-14 DOI: 10.1080/09546634.2023.2216323

Ferial Fanian, Jean-Jacques Deutsch, Marie Thérèse Bousquet, Sylvie Boisnic, Pierre Andre, Isabelle Catoni, Ghislaine Beilin, Christian Lemmel, Maryna Taieb, Marie Gomel-Toledano, Hanane Issa, Philippe Garcia

{"title":"A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study.","authors":"Ferial Fanian, Jean-Jacques Deutsch, Marie Thérèse Bousquet, Sylvie Boisnic, Pierre Andre, Isabelle Catoni, Ghislaine Beilin, Christian Lemmel, Maryna Taieb, Marie Gomel-Toledano, Hanane Issa, Philippe Garcia","doi":"10.1080/09546634.2023.2216323","DOIUrl":"10.1080/09546634.2023.2216323","url":null,"abstract":"Background: NCTF®135HA is a bio-revitalizing solution containing hyaluronic acid designed to compensate for skin dehydration, fatigue, and fine wrinkles associated with endogenous and environmental aging.Methods: We conducted a randomized, active-controlled study to evaluate the efficacy and tolerability of NCTF®135HA injections on the face (crow's feet), neck, and décolleté regions. Subjects were randomly assigned (3:1) to receive three NCTF®135HA treatment sessions plus twice-daily anti-aging moisturizer cream or cream alone (control). The primary outcome was the reduction in superficial wrinkles between baseline and Day (D)75 in the three areas, assessed by profilometric measures, clinical scoring, subjective changes, and tolerability.Results: 146 subjects were randomized to NCTF®135HA (n = 107) or control (n = 38). At D75 and D120, NCTF®135HA significantly reduced wrinkles in all three areas and improved facial radiance scores compared with the control. Skin hydration significantly increased 7 d after the last NCTF®135HA injection. Self-esteem scales showed statistically significant improvements at D75 and D120 in subjects treated with NCTF®135HA versus baseline. Most adverse events were mild, resolved within 48 h, and were related to the injection procedure.Conclusion: NCTF®135HA is an effective and well-tolerated treatment to reduce the skin signs of aging. The results are significantly superior to a routine anti-aging cream alone.(Funded by Laboratories FILLMED; ID-RCB number: 2018-A03167-48; clinicaltrials.gov number: NCT05609617).","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"34 1","pages":"2216323"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9981538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A prospective randomized controlled trial of Psychodermatology on the efficacy of Rilastil Difesa Sterile® cream in the hand eczema of healthcare workers during the COVID-19 pandemic. 新冠肺炎大流行期间，皮肤病学关于Rilastil Difesa无菌®霜治疗医护人员手部湿疹疗效的前瞻性随机对照试验。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 DOI: 10.1080/09546634.2023.2245080

Federica Veronese, Elia Esposto, Chiara Airoldi, Carla Gramaglia, Lucia Bestagini, Elisa Zavattaro, Patrizia Zeppegno, Paola Savoia

{"title":"A prospective randomized controlled trial of Psychodermatology on the efficacy of Rilastil Difesa Sterile® cream in the hand eczema of healthcare workers during the COVID-19 pandemic.","authors":"Federica Veronese, Elia Esposto, Chiara Airoldi, Carla Gramaglia, Lucia Bestagini, Elisa Zavattaro, Patrizia Zeppegno, Paola Savoia","doi":"10.1080/09546634.2023.2245080","DOIUrl":"10.1080/09546634.2023.2245080","url":null,"abstract":"Hand eczema is one of the most frequent dermatological diseases, with an incidence increased during the COVID-19 pandemic. The impact on life quality is considerable, giving rise to the need for a psycho-dermatological approach. This is a Randomized Control Trial (RCT) evaluating, either by the dermatological or psychological point of view, the effectiveness of an emollient and rehydrating topical product (Rilastil Difesa Sterile® cream) versus a standard treatment (i.e. moisturizing basic cream) in a group of 51 healthcare workers suffering from hand eczema during the COVID-19 pandemic. The enrolled subjects were randomized into a treatment or a control arm, treated for 8 weeks, and monitored through a clinical score (HECSI) and questionnaires evaluating the impact of the pathology and treatment on quality of life (DLQI and QOLHEQ). A psychometric evaluation was performed using the SCL-90 R, OCI-R, and CPDI scales. Our data, despite not reaching the statistical significance, demonstrated that both the clinical and psychological scores decreased mostly in patients treated with Rilastil Difesa Sterile® cream when compared to those treated with simple topical emollients. Moreover, we observed a high level of psychic suffering in dermatological patients and a parallel change in dermatological and psychological indicators, thus confirming their connection.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"34 1","pages":"2245080"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10344204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of rare linear lichen planopilaris with Ixekizumab. Ixekizumab成功治疗罕见线状扁平苔藓。

IF 3.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 DOI: 10.1080/09546634.2023.2201364

Hanof Ahmed, Mahir Petkar, Martin Steinhoff

{"title":"Successful treatment of rare linear lichen planopilaris with Ixekizumab.","authors":"Hanof Ahmed, Mahir Petkar, Martin Steinhoff","doi":"10.1080/09546634.2023.2201364","DOIUrl":"10.1080/09546634.2023.2201364","url":null,"abstract":"Background: Lichen planopilaris (LPP) is a lymphocytic primary cicatricial alopecia characterized by perifollicular erythema, follicular hyperkeratosis and scaring, resulting in permanent hair loss. Current treatment modalities, both topical and systemic, fail to achieve satisfactory and consistent results. As therapies fail to halt the inflammatory process, patients with LPP may face long-term disfigurement and significant psychological burden.Purpose: To initiate an efficacious targeted therapy with good tolerability and low side effect profile that will allow hair regrowth and prevent the development to disfiguring alopecia.Materials and methods: Here, we report on a case of rare LPP in a linear distribution (LLPP) involving the scalp and forehead failing to achieve satisfactory results with continued hair loss with multiple previous treatments.Results: Complete hair regrowth was achieved 12 weeks after treatment with an anti-psoriatic, anti-interleukin (IL)-17A/F antibody (Taltz, Ixekizumab, Lilly). Patient continued to display sustained efficacy with no reported side effects until 12 months on treatment.Conclusions: The present case underlines the viability of Ixekizumab as a possible first-line, targeted therapy for LPP and its variants with sustained efficacy. Multicenter trials are warranted to confirm the benefit of Ixekizumab as a successful targeted biologic treatment option for LPP and LLPP.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"34 1","pages":"2201364"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10261573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An international expert consensus statement focusing on pre and post hair transplantation care. 一份国际专家共识声明，重点关注毛发移植前后的护理。

IF 3.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 DOI: 10.1080/09546634.2023.2232065

S Vañó-Galván, C N Bisanga, P Bouhanna, B Farjo, V Gambino, T Meyer-González, T Silyuk

{"title":"An international expert consensus statement focusing on pre and post hair transplantation care.","authors":"S Vañó-Galván, C N Bisanga, P Bouhanna, B Farjo, V Gambino, T Meyer-González, T Silyuk","doi":"10.1080/09546634.2023.2232065","DOIUrl":"10.1080/09546634.2023.2232065","url":null,"abstract":"Aim: To achieve international expert consensus and give recommendations on best practices in hair transplantation surgery, focusing on pre- and post-transplantation care.Methods: A modified Delphi method was used to reach consensus. An international scientific committee developed an 81-statement questionnaire. A panel of 38 experts in hair transplantation from 17 countries across 4 continents assessed the questionnaire.Results: Two consensus rounds were carried out, with 59 out of 81 statements (73%) reaching consensus. Expert recommendations emphasize the correct selection of candidates for hair transplantation and the need for patients to have received adequate medical treatment for alopecia before transplant. Comorbidities should be assessed and considered while planning surgery, and an individualized plan for perioperative care should be drawn up before transplant. Certain medications associated with increased risk of bleeding should be withdrawn before surgery. Specific recommendations for post-transplantation care are given. After transplantation, patients should gradually resume their normal haircare regimen. Close follow-up should be carried out during the first year after transplant.Conclusions: This study presents numerous consensus-based recommendations on general aspects of hair transplantation, including candidate selection, medical therapy prior to transplantation, anesthesia, and resuming haircare after transplantation.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"34 1","pages":"2232065"},"PeriodicalIF":3.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9849490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan 中重度特应性皮炎患者从巴利昔尼 4 毫克换药至达帕替尼 30 毫克的疗效：日本的实际临床实践

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 DOI: 10.1080/09546634.2023.2276043

Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, E. Fujimoto, N. Kanda

{"title":"Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan","authors":"Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, E. Fujimoto, N. Kanda","doi":"10.1080/09546634.2023.2276043","DOIUrl":"https://doi.org/10.1080/09546634.2023.2276043","url":null,"abstract":"Abstract Background Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibitor to another have not been examined. Objectives We assessed the outcomes of switching from baricitinib 4 mg to upadacitinib 30 mg in Japanese patients with moderate-to-severe AD. Methods Twenty patients treated with baricitinib 4 mg, showing insufficient response or adverse events, were switched to treatment with upadacitinib 30 mg. We evaluated total eczema area and severity index (EASI), EASI at head and neck, trunk, upper, or lower limbs, EASI of erythema, edema/papulation, excoriation, or lichenification, and peak pruritus numerical-rating scale (PP-NRS) at baseline (start of baricitinib), weeks 0 (time of switching), and 4 and 12 after switching. Results Total EASI, EASI at each anatomical site, EASI of each clinical sign, and PP-NRS were markedly reduced at weeks 4 or 12 compared to week 0. Achievement rates of more than 75% or 90% reduction of EASI from baseline significantly improved after switching. Conclusions Switching from baricitinib 4 mg to upadacitinib 30 mg effectively improved rash and pruritus.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"1 21","pages":""},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138609943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0